ABOUT

About Us

About Hemay

Innovation-driven, Global Layout

Hemay Pharmaceutical, founded in 2002, is a pharmaceutical enterprise dedicated to the independent research and development (R&D) and industrialization of global innovative drugs. Guided by unmet clinical needs in its R&D efforts, the company adheres to the development objective of "rooting in China and targeting the global market" and proactively carries out global layout in terms of projects, patents, and industrial chains. It has established multiple subsidiaries, covering all functional segments from R&D to production.



Overcome the bottlenecks inherent in classical paradigms and create exceptional clinical value.

Hemay has consistently upheld its mission of "developing more effective, safer, and more cost-efficient novel drugs for patients" and adhered to the principle of "being accountable to patients". Through interdisciplinary collaboration and scientific innovation, the company is actively striving to build a world-class research, development, and manufacturing hub for value-driven pharmaceuticals.

In its R&D endeavors, Hemay avoids unreflective pursuit of emerging targets or trending research areas. Instead, it persists in leveraging its proprietary R&D platforms and core technologies as the foundation, focusing on creating products with exceptional clinical value. The company’s R&D pipeline spans therapeutic areas including autoimmune diseases and oncology, with multiple indications already in the NDA (New Drug Application) stage or pivotal clinical trial phase.

Hemay’s projects have repeatedly garnered recognition and support from government agencies at all levels and research institutions. To date, Hemay has independently undertaken three projects under the National Science and Technology Major Project of "Major New Drug Innovation".


"Harmony" for co-creation, "Beauty" for a bright future

Hemay adheres to an "open and grateful" mindset, actively seeking opportunities for win-win cooperation, and has gained wide recognition and support from all sectors. Hemay has not only established long-term strategic partnerships with many pharmaceutical enterprises (institutions), but also carried out multiple fruitful research and development collaborations with renowned universities. As the projects and the company develop, the company's value has been further recognized by the market and capital. Hemay has received multiple rounds of investment from many top venture funds and investors. Hemay looks forward to working with you to achieve the ideal and goal of "enabling the world to use good drugs developed by the Chinese".


3
varietieshave been approved for the National "Major New Drug Creation" Science and Technology Major Project.
5
Class 1 Innovative Drugs10+ clinical trials for indications
4
varietiesproduct candidates are in Clinical Phase II, Phase III, and New Drug Application (NDA) stages.
74
items
Chinese Invention Patents
29
itemsinternational PCT (Patent Cooperation Treaty) patents
100+
itemsforeign-authorized patents

Development Milestones

2002-2013
2014-2015
2015-2018
2019-2020
2021-2022
2023----

2002-2013

  • In 2002, Hemay was founded, and Tianjin Hemay Biotechnology Co., Ltd. was established to carry out preclinical research on multiple projects.
  • We submitted the application for IND approval in respect of Mufemilast.
  • We submitted the application for IND approval in respect of Hemay022

2014-2015

  • Hemay Holding completed the first round of financing
  • We obtained from NMPA an IND approval in respect of treatment of Ps with Mufemilast.

2015-2018

  • We conducted our first clinical trial in Australia, with efforts to commence our overseas research and development.
  • We completed the Phase I clinical trial of Mufemilast on single-dose and food effects study.
  • The Phase I clinical trial of Mufemilast on multiple-dose safety and pharmacokinetics.

2019-2020

  • Ganzhou Hemay Pharmaceutical Co., Ltd. was formally established
  • the Phase I clinical trial of Mufemilast on multiple-dose safety and pharmacokinetics
  • the Phase I clinical trial of Mufemilast on multiple-dose safety and pharmacokinetics
  • the Phase I clinical trial of Mufemilast on multiple-dose safety and pharmacokinetics

2021-2022

  • the Phase I clinical trial of Mufemilast on multiple-dose safety and pharmacokinetics
  • We completed Series C financing.
  • We initiated the Phase II clinical trial of Mufemilast for the treatment of BD.
  • The Phase III clinical trial of Mufemilast for psoriasis (Ps) has been initiated.
  • We completed the Phase Ib clinical trial for Hemay022 in combination with endocrine drugs.
  • We initiated the Phase III clinical trial for Hemay022 for the treatment of breast cancer.
  • We entered into the capital increase agreement for Series D financing

2023----

  • Our Company was converted into a joint stock limited liability company, and renamed as Ganzhou Hemay Pharmaceutical Co., Ltd.
  • We obtained from FDA orphan drug designation in respect of Mufemilast.
  • We completed the Phase III clinical trial of Mufemilast for the treatment of Ps.
  • We initiated the Phase II clinical trial of Mufemilast for the treatment of UC.
  • We initiated the Phase I clinical trial of Hemay181 for the treatment of late-stage solid tumors in the PRC, and obtained an IND approval from FDA to begin the Phase I clinical trial of Hemay181 in the United States.
  • We completed Series D+ financing